Table 2.
Enhancement Factors for the induction of SSB, DSB and interduplex CL as a function of the number of Pt-adducts per nucleotide. S1 and S2 denote the slopes of the fitted lines to the Enhancement Factor curves for the DNA damages presented in Fig. 3 at ratios less and more that 3.1 × 10−4 Pt-adducts per nucleotide, respectively. R1,2 is the ratio of S1 to S2.
| DNA Damage* | Pt-drug | S1 (× 103) | S2 (× 103) | R1,2 |
|---|---|---|---|---|
| SSB | Cisplatin | 0.51 ± 0.03 | 0.51 ± 0.03 | 1 ± 0.1 |
| Carboplatin | 0.57 ± 0.04 | 0.57 ± 0.04 | 1 ± 0.1 | |
| Oxaliplatin | 0.56 ± 0.06 | 0.56 ± 0.06 | 1 ± 0.1 | |
|
| ||||
| DSB | Cisplatin | 4.8 ± 0.2 | 0.54 ± 0.07 | 8.9 ± 1.1 |
| Carboplatin | 6.7 ± 0.8 | 0.65 ± 0.1 | 10.3 ± 2.0 | |
| Oxaliplatin | 4.5 ± 0.6 | 0.59 ± 0.1 | 7.6 ± 1.6 | |
|
| ||||
| CL | Cisplatin | 3.84 ± 0.2 | 0.65 ± 0.06 | 5.9 ± 0.8 |
| Carboplatin | 6.4 ± 0.9 | 0.62 ± 0.08 | 10.3 ± 1.9 | |
| Oxaliplatin | 9.5 ± 2.6 | 0.67 ± 0.03 | 14.2 ± 3.9 | |
*
SSB: single strand break; DSB: double strand break; CL: interduplex cross-link